Efficacy and tolerability of immucytal® in the prevention and treatment of respiratory tract infections in adults: A randomized, placebo-controlled, double-blind study

International Journal of Immunotherapy

Volumn 17, Issue 1, 2001, Pages 31-40

  Galioto, G B ^a   Galioto, P ^a   Mevio, E ^a   Mora, E ^a   Bardieri, M ^a   Mora, R ^a   Mora, F ^a   Ottaviani, A ^a   Ottaviani, F ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOSTIMULATING AGENT; PLACEBO; RIBOMUNYL;

ADULT; AGE; AGED; ARTICLE; BRONCHITIS; CLINICAL TRIAL; CONSULTATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; EVALUATION; FEVER; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL PARAMETERS; IMMUNOSTIMULATION; IMMUNOTHERAPY; INCIDENCE; INFECTION PREVENTION; LOWER RESPIRATORY TRACT INFECTION; LUNG FUNCTION; MAJOR CLINICAL STUDY; MEDICAL PARAMETERS; MORBIDITY; MUCOSAL IMMUNITY; MULTICENTER STUDY; PARALLEL DESIGN; PHYSICIAN; RANDOMIZED CONTROLLED TRIAL; RECURRENT INFECTION; RESPIRATORY TRACT INFECTION; RIBOSOME; SCORING SYSTEM; SIDE EFFECT; TABLET; TREATMENT PLANNING; UNIVERSITY HOSPITAL; UPPER RESPIRATORY TRACT INFECTION;

EID: 0035211137     PISSN: 02559625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Infections of the ear, nose and throat
2. Sinusitis
3. Current estimates from the National Health Interview Survey, 1993
4. Recurrent respiratory tract infections in pediatric patients
5. Epidemiology of otitis media
6. Economic evaluation of ribosomal immunotherapy in patients with chronic ear, nose and throat and respiratory tract infections: Results for Italy
7. Cost effectiveness of immunoprophylaxis in the prevention of recurrent infectious rhinitis in adults
8. Epidemiology of upper respiratory tract and bronchopulmonary infections. A study of 221 pathogens from 202 samples
9. ®)
10. Immunoglobulin production in man stimulated by orally administered bacterial lysate (Broncho-Vaxom)
11. Prevention of bacterial respiratory infections using a ribosomal vaccine
12. Oral administration of streptococcal antigen coupled to cholera toxin B subunit evokes strong antibody responses in salivary glands and extramucosal tissues
13. Biological activity of bacterial cell wall components: Immunogenicity of an immunostimulating bacterial extract
14. The mucosal immune system. From fundamental concepts to vaccine development
15. Bacterial adherence and upper respiratory tract disease: A correlation between S. pyogenes attachment and recurrent throat infections
16. Cytokine and Ig-producing cells in mucosal effector tissues: Analysis of IL-5 and IFN-γ producing cells, T cells, T cell receptor expression and IgA plasma cells from mouse salivary gland-associated tissues
17. Immunoglobulin A. (IgA): Molecular and cellular interactions involved in IgA biosynthesis and immune response
18. Overview of the mucosal immune system
19. The common mucosal immune system and current strategies for induction of immune responses in external secretions
20. Stimulation of NK cells using Klebsiella Pneumoniae membrane proteoglycans
21. Stimulation of cytotoxic and non-cytotoxic functions of natural killer cells by bacterial membrane proteoglycans and ribosomes
22. Chemotactic cytokine gene expression and production induced in human monocytes by membrane proteoglycans from Klebsiella Pneumoniae
23. Bacterial ribosomal immunostimulants prime alveolar macrophages in vivo to produce interleukin 1 in vitro
24. Effect of an in vivo immunostimulant treatment on PMN functions: Interaction with antibiotics in vitro
25. Immunostimulant effects on granulocyte functions during an acute respiratory infection
26. Antibody-producing cells in peripheral blood and tonsils after oral treatment of children with bacterial ribosomes
27. Recurrent respiratory infections in children
28. ® in the prevention and treatment of recurrent upper respiratory tract infections in children: A randomised, placebo-controlled, double-blind study
29. ® in the prevention of recurrent upper respiratory tract infections
30. Clinical experience with Biomunil tablets in children with recurrent respiratory infections
31. Prophylaxis of recurrent respiratory infections in children with a new immunomodulating agent
32. ® tablets in preventing middle ear infections in children affected by SOM
33. ® tablets in children aged less than 5 years
34. Prevention of recurrent ear, nose and throat infections in young children with Ribomunyl®: Double-blind, placebo-controlled study
35. Effectiveness of ribosomal fractions of Klebsiella pneumoniae, Streptococcus pneumoniae, Streptococcus pyogenes, Haemophilus influenzae and the membrane fraction of Kp (Ribomunyl) in the prevention of clinical infectious rhinitis: Results of a multicenter double-blind placebo-controlled study
36. Relapsing tonsilitis: Prevention with a ribosomal vaccine
37. The place of different forms of Ribomunyl in the treatment of recurrent respiratory tract infections